- Year selection
- 2022
- 2033
-
2024-05-24
VOLUNTARY ANNOUNCEMENT - PHASE II STUDY DATA OF M701 FOR THE TREATMENT OF MALIGNANT ASCITES PRESENTED AT THE 2024 ASCO MEETING
-
2024-05-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
-
2024-04-30
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
-
2024-04-30
RESIGNATION OF NON-EXECUTIVE DIRECTOR
-
2024-04-26
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
-
2024-04-26
2023 ANNUAL REPORT
-
2024-04-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
-
2024-03-28
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
-
2024-03-27
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF M701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANT ASCITES
-
2024-03-26
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT ENROLLED IN PHASE II CLINICAL TRIAL OF M701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANT PLEURAL EFFUSION
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
